000167446 001__ 167446
000167446 005__ 20240229133540.0
000167446 0247_ $$2pmid$$apmid:33578373
000167446 0247_ $$2ISSN$$a1540-1405
000167446 0247_ $$2ISSN$$a1540-1413
000167446 0247_ $$2doi$$adoi: 10.6004/jnccn.2020.7636.
000167446 037__ $$aDKFZ-2021-00350
000167446 041__ $$aeng
000167446 082__ $$a610
000167446 1001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b0$$eFirst author$$udkfz
000167446 245__ $$aUptake Rates of Novel Therapies and Survival Among Privately Insured Versus Publicly Insured Patients With Colorectal Cancer in Germany.
000167446 260__ $$aCold Spring Harbor, NY$$bHarborside Press$$c2021
000167446 3367_ $$2DRIVER$$aarticle
000167446 3367_ $$2DataCite$$aOutput Types/Journal article
000167446 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625043661_24032
000167446 3367_ $$2BibTeX$$aARTICLE
000167446 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167446 3367_ $$00$$2EndNote$$aJournal Article
000167446 500__ $$a#EA:C070#LA:C070# / 19(4):411-420
000167446 520__ $$aIn the era of personalized medicine, cancer care is subject to major changes and innovations. It is unclear, however, to what extent implementation of such innovations and their impact on patient outcomes differ by health insurance type. This study compared provision of treatment and survival outcomes among patients with colorectal cancer (CRC) who had statutory health insurance (SHI) versus private health insurance (PHI) in Germany.We analyzed patterns of CRC treatment (surgery, chemotherapy/radiotherapy, and targeted therapy) and survival in a large cohort of patients who were diagnosed with CRC in 2003 through 2014 and were observed for an average of 6 years. Associations of type of health insurance with treatment administration and with overall, CRC-specific, and recurrence-free survival were investigated using multivariable logistic and Cox proportional hazards models, respectively.Of 3,977 patients with CRC, 427 (11%) had PHI. Although type of health insurance was not associated with treatment administration in patients with stage I-III disease, those with stage IV disease with PHI more often received targeted therapy (65% vs 40%; odds ratio, 2.43; 95% CI, 1.20-4.91), with differences decreasing over time because of catch-up of uptake rates in patients with SHI. Median overall survival was longer in patients with PHI than in those with SHI (137.0 vs 114.9 months; P=.010), but survival advantages were explained to a large extent by differences in sociodemographic factors. In patients with stage IV disease, survival advantages of PHI were nonsignificant and were restricted to the early years after diagnosis.We observed major differences in uptake of targeted therapy between patients with PHI and those with SHI but no differences in patient survival after adjusting for relevant sociodemographic, clinical, and tumor characteristics. Further studies are needed on factors associated with the uptake of therapeutic innovations and their impact on patient survival by health insurance type.
000167446 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167446 588__ $$aDataset connected to PubMed,
000167446 7001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b1$$udkfz
000167446 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b2$$udkfz
000167446 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence R$$b3$$udkfz
000167446 7001_ $$aReissfelder, Christoph$$b4
000167446 7001_ $$aSchneider, Martin$$b5
000167446 7001_ $$aMartens, Uwe M$$b6
000167446 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$udkfz
000167446 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000167446 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000167446 773__ $$0PERI:(DE-600)2134524-7$$a10.6004/jnccn.2020.7636.$$n4$$p411-420$$tJournal of the National Comprehensive Cancer Network$$v19$$x1540-1405$$y2021
000167446 909CO $$ooai:inrepo02.dkfz.de:167446$$pVDB
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000167446 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000167446 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167446 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167446 9141_ $$y2021
000167446 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NATL COMPR CANC NE : 2018$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-12
000167446 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NATL COMPR CANC NE : 2018$$d2020-09-12
000167446 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000167446 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000167446 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000167446 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000167446 980__ $$ajournal
000167446 980__ $$aVDB
000167446 980__ $$aI:(DE-He78)C070-20160331
000167446 980__ $$aI:(DE-He78)C020-20160331
000167446 980__ $$aI:(DE-He78)C120-20160331
000167446 980__ $$aI:(DE-He78)HD01-20160331
000167446 980__ $$aUNRESTRICTED